Acute lymphocytic leukemia market developments

The market for acute lymphocytic leukemia (ALL), the most commonly diagnosed form of leukemia, is expected to see strong growth at a compound annual growth rate (CAGR) of 5% over the next decade across the world’s eight major markets (8MM).

This is driven primarily by the increased use of cell therapies, with the CAR-T market alone expected to reach $1.2 billion in 2031, accounting for 40% of the total ALL market, according to data and analytics company GlobalData.

GlobalData’s latest report, “ Acute Lymphocytic Leukemia (ALL): Cell Therapies 15-Market Assessment and Forecast,” reveals that Novartis’ (NOVN: VX) anti-CD19 CAR-T therapy, Kymriah (tisagenlecleucel), is expected to retain its position as the market-leading ALL brand, with label expansion into front-line therapy and uptake in additional markets driving substantial growth.